



95TH GENERAL ASSEMBLY

State of Illinois

2007 and 2008

SB0030

Introduced 1/31/2007, by Sen. David Luechtefeld

SYNOPSIS AS INTRODUCED:

See Index

Amends the Illinois Controlled Substances Act. Requires the Department of Human Services to establish an electronic system for monitoring Schedules II, III, IV, and V controlled substances that are dispensed within the State by a practitioner or pharmacist or dispensed to an address within the State by a pharmacy that has obtained a license, permit, or other authorization to operate from the Department of Financial and Professional Regulation. Provides that every dispenser within the State or any other dispenser who has obtained a license, permit, or other authorization to operate from the Department of Financial and Professional Regulation shall report to the Department specified data in a timely manner as prescribed by the Department except that reporting shall not be required for a drug administered directly to a patient or a drug dispensed by a practitioner at a facility licensed by the Department provided that the quantity dispensed is limited to an amount adequate to treat the patient for a maximum of 48 hours. Provides that data for each controlled substance that is dispensed shall include but not be limited to: patient identifier; drug dispensed; date of dispensing; quantity dispensed; prescriber; and dispenser. Provides that the Department of Human Services shall submit an application to the United States Department of Justice for a drug diversion grant to fund a pilot project to study a real-time electronic monitoring system for Schedules II, III, IV, and V controlled substances. Repeals provisions establishing the Schedule II controlled substance prescription monitoring program. Makes other changes. Effective January 1, 2008.

LRB095 04252 RLC 24293 b

CORRECTIONAL
BUDGET AND
IMPACT NOTE ACT
MAY APPLY

FISCAL NOTE ACT
MAY APPLY

A BILL FOR

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 313 and 406 and adding Section
6 316.5 as follows:

7 (720 ILCS 570/313) (from Ch. 56 1/2, par. 1313)

8 Sec. 313. (a) Controlled substances which are lawfully
9 administered in hospitals or institutions licensed under the
10 "Hospital Licensing Act" shall be exempt from the requirements
11 of Sections 312 and 316 except that the prescription for the
12 controlled substance shall be in writing on the patient's
13 record, signed by the prescriber, dated, and shall state the
14 name, and quantity of controlled substances ordered and the
15 quantity actually administered. The records of such
16 prescriptions shall be maintained for two years and shall be
17 available for inspection by officers and employees of the
18 Department of State Police, and the Department of Professional
19 Regulation.

20 (b) Controlled substances that can lawfully be
21 administered or dispensed directly to a patient in a long-term
22 care facility licensed by the Department of Public Health as a
23 skilled nursing facility, intermediate care facility, or

1 long-term care facility for residents under 22 years of age,
2 are exempt from the requirements of Section 312 except that a
3 prescription for a Schedule II controlled substance must be
4 either a written prescription signed by the prescriber or a
5 written prescription transmitted by the prescriber or
6 prescriber's agent to the dispensing pharmacy by facsimile. The
7 facsimile serves as the original prescription and must be
8 maintained for 2 years from the date of issue in the same
9 manner as a written prescription signed by the prescriber.

10 (c) A prescription that is written for a Schedule II
11 controlled substance to be compounded for direct
12 administration by parenteral, intravenous, intramuscular,
13 subcutaneous, or intraspinal infusion to a patient in a private
14 residence, long-term care facility, or hospice setting may be
15 transmitted by facsimile by the prescriber or the prescriber's
16 agent to the pharmacy providing the home infusion services. The
17 facsimile serves as the original written prescription for
18 purposes of this paragraph (c) and it shall be maintained in
19 the same manner as the original written prescription.

20 (c-1) A prescription written for a Schedule II controlled
21 substance for a patient residing in a hospice certified by
22 Medicare under Title XVIII of the Social Security Act or
23 licensed by the State may be transmitted by the practitioner or
24 the practitioner's agent to the dispensing pharmacy by
25 facsimile. The practitioner or practitioner's agent must note
26 on the prescription that the patient is a hospice patient. The

1 facsimile serves as the original written prescription for
2 purposes of this paragraph (c-1) and it shall be maintained in
3 the same manner as the original written prescription.

4 (d) Controlled substances which are lawfully administered
5 and/or dispensed in drug abuse treatment programs licensed by
6 the Department shall be exempt from the requirements of
7 Sections 312 and 316.5 ~~316~~, except that the prescription for
8 such controlled substances shall be issued and authenticated on
9 official prescription logs prepared and supplied by the
10 Department. The official prescription logs issued by the
11 Department shall be printed in triplicate on distinctively
12 marked paper and furnished to programs at reasonable cost. The
13 official prescription logs furnished to the programs shall
14 contain, in preprinted form, such information as the Department
15 may require. The official prescription logs shall be properly
16 endorsed by a physician licensed to practice medicine in all
17 its branches issuing the order, with his own signature and the
18 date of ordering, and further endorsed by the practitioner
19 actually administering or dispensing the dosage at the time of
20 such administering or dispensing in accordance with
21 requirements issued by the Department. The duplicate copy shall
22 be retained by the program for a period of not less than three
23 years nor more than seven years; the original and triplicate
24 copy shall be returned to the Department at its principal
25 office in accordance with requirements set forth by the
26 Department.

1 (Source: P.A. 91-576, eff. 4-1-00; 91-714, eff. 6-2-00.)

2 (720 ILCS 570/316.5 new)

3 Sec. 316.5. Electronic system for monitoring controlled
4 substances.

5 (a) The Department shall establish an electronic system for
6 monitoring Schedules II, III, IV, and V controlled substances
7 that are dispensed within the State by a practitioner or
8 pharmacist or dispensed to an address within the State by a
9 pharmacy that has obtained a license, permit, or other
10 authorization to operate from the Department of Financial and
11 Professional Regulation.

12 (b) A practitioner or a pharmacist shall not have to pay a
13 fee or tax specifically dedicated to the operation of the
14 system.

15 (c) Every dispenser within the State or any other dispenser
16 who has obtained a license, permit, or other authorization to
17 operate from the Department of Financial and Professional
18 Regulation shall report to the Department the data required by
19 this Section in a timely manner as prescribed by the Department
20 except that reporting shall not be required for: (1) a drug
21 administered directly to a patient; or (2) a drug dispensed by
22 a practitioner at a facility licensed by the Department
23 provided that the quantity dispensed is limited to an amount
24 adequate to treat the patient for a maximum of 48 hours.

25 (d) Data for each controlled substance that is dispensed

1 shall include but not be limited to the following: (1) patient
2 identifier; (2) drug dispensed; (3) date of dispensing; (4)
3 quantity dispensed; (5) prescriber; and (6) dispenser.

4 (e) The data shall be provided in the electronic format
5 specified by the Department unless a waiver has been granted by
6 the Department to an individual dispenser. The Department shall
7 establish acceptable error tolerance rates for data.
8 Dispensers shall ensure that reports fall within these
9 tolerances. Incomplete or inaccurate data shall be corrected
10 upon notification by the Department if the dispenser exceeds
11 these error tolerance rates.

12 (f) The Department shall be authorized to provide data to:
13 (1) a designated representative of the Department of Financial
14 and Professional Regulation who is involved in a bona fide
15 specific investigation involving a designated person; (2) an
16 Illinois peace officer, a certified or full-time peace officer
17 of another state, or a federal peace officer whose duty is to
18 enforce the laws of this State, of another state, or of the
19 United States relating to drugs and who is engaged in a bona
20 fide specific investigation involving a designated person; (3)
21 a state-operated Medicaid program; (4) a properly convened
22 grand jury pursuant to a subpoena properly issued for the
23 records; (5) a practitioner or pharmacist who requests
24 information and certifies that the requested information is for
25 the purpose of providing medical or pharmaceutical treatment to
26 a bona fide current patient; (6) in addition to the purposes

1 authorized under paragraph (1) of this subsection, the
2 Department of Financial and Professional Regulation, for any
3 physician who is: (i) associated in a partnership or other
4 business entity with a physician who is already under
5 investigation by the Department of Financial and Professional
6 Regulation for improper prescribing practices; (ii) in a
7 designated geographic area for which a trend report indicates a
8 substantial likelihood that inappropriate prescribing may be
9 occurring; or (iii) in a designated geographic area for which a
10 report on another physician in that area indicates a
11 substantial likelihood that inappropriate prescribing may be
12 occurring in that area; (7) in addition to the purposes
13 authorized under paragraph (1) of this subsection, the
14 Department of Financial and Professional Regulation, for any
15 advanced practice nurse who is: (i) associated in a partnership
16 or other business entity with a physician who is already under
17 investigation by the Department of Financial and Professional
18 Regulation for improper prescribing practices; (ii) associated
19 in a partnership or other business entity with an advanced
20 practice nurse practitioner who is already under investigation
21 by the Department of Financial and Professional Regulation for
22 improper prescribing practices; (iii) in a designated
23 geographic area for which a trend report indicates a
24 substantial likelihood that inappropriate prescribing may be
25 occurring; or (iv) in a designated geographic area for which a
26 report on a physician or another advanced practice nurse

1 practitioner in that area indicates a substantial likelihood
2 that inappropriate prescribing may be occurring in that area;
3 or (8) a judge or a probation officer or parole agent
4 administering a diversion or probation program of a criminal
5 defendant arising out of a violation of this Act or of a
6 criminal defendant who is documented by the court as a
7 substance abuser who is eligible to participate in a
8 court-ordered drug diversion or probation program.

9 (g) The Department of Healthcare and Family Services may
10 use any data or reports from the system for the purpose of
11 identifying Medicaid recipients whose usage of controlled
12 substances may be appropriately managed by a single outpatient
13 pharmacy or primary care physician.

14 (h) A person who receives data or any report of the system
15 from the Department shall not provide it to any other person or
16 entity except by order of a court of competent jurisdiction,
17 except that: (1) a peace officer specified in paragraph (f) (2)
18 of this Section who is authorized to receive data or a report
19 may share that information with other peace officers specified
20 in paragraph (f) (2) of this Section authorized to receive data
21 or a report if the peace officers specified in paragraph (f) (2)
22 of this Section are working on a bona fide specific
23 investigation involving a designated person. Both the person
24 providing and the person receiving the data or report under
25 this subsection shall document in writing each person to whom
26 the data or report has been given or received and the day,

1 month, and year that the data or report has been given or
2 received. This document shall be maintained in a file by each
3 law enforcement agency engaged in the investigation; and (2) a
4 representative of the Department of Healthcare and Family
5 Services may share data or reports regarding overutilization by
6 Medicaid recipients with the Department of Financial and
7 Professional Regulation or with a law enforcement officer
8 designated in paragraph (f)(2) of this Section; and (3) the
9 Department of Healthcare and Family Services may submit the
10 data as evidence in an administrative hearing held in
11 accordance with the Illinois Administrative Procedure Act.

12 (i) The Department, all peace officers specified in
13 paragraph (f)(2) of this Section, all officers of the court,
14 and all regulatory agencies and officers, in using the data for
15 investigative or prosecution purposes, shall consider the
16 nature of the prescriber's and dispenser's practice and the
17 condition for which the patient is being treated.

18 (j) The data and any report obtained therefrom shall not be
19 a public record, except that the Department of Healthcare and
20 Family Services may submit the data as evidence in an
21 administrative hearing held in accordance with the Illinois
22 Administrative Procedure Act.

23 (k) Knowing failure by a dispenser to transmit data to the
24 Department as required by subsection (c), (d), or (e) of this
25 Section is a Class A misdemeanor.

26 (l) Knowing disclosure of transmitted data to a person not

1 authorized by subsections (f) to (h) of this Section or
2 authorized by the Pharmacy Practice Act of 1987, or obtaining
3 information under this Section not relating to a bona fide
4 specific investigation, is a Class 4 felony.

5 (m) The Department shall submit an application to the
6 United States Department of Justice for a drug diversion grant
7 to fund a pilot project to study a real-time electronic
8 monitoring system for Schedules II, III, IV, and V controlled
9 substances. The pilot project shall: (1) be conducted in 2
10 rural counties that have an interactive real-time electronic
11 information system in place for monitoring patient utilization
12 of health and social services through a federally funded
13 community access program; and (2) study the use of an
14 interactive system that includes a relational data base with
15 query capability.

16 (n) Provisions in this Section that relate to data
17 collection, disclosure, access, and penalties shall apply to
18 the pilot project authorized under subsection (m) of this
19 Section.

20 (o) The Department may limit the length of time that data
21 remain in the electronic system. Any data removed from the
22 system shall be archived and subject to retrieval within a
23 reasonable time after a request from a person authorized to
24 review data under this Section.

25 (p)(1) The Department shall work with the Department of
26 Financial and Professional Regulation for the development of a

1 continuing education program about the purposes and uses of the
2 electronic system for monitoring established in this Section.

3 (2) The Attorney General shall work with the Illinois State
4 Bar Association for the development of a continuing education
5 program for attorneys about the purposes and uses of the
6 electronic system for monitoring established in this Section.

7 (3) The Department shall work with the Illinois Law
8 Enforcement Training Standards Board for the development of a
9 continuing education program for law enforcement officers
10 about the purposes and users of the electronic system for
11 monitoring established in this Section.

12 (720 ILCS 570/406) (from Ch. 56 1/2, par. 1406)

13 Sec. 406. (a) It is unlawful for any person:

14 (1) who is subject to Article III knowingly to
15 distribute or dispense a controlled substance in violation
16 of Sections 308 through 314 of this Act; or

17 (2) who is a registrant, to manufacture a controlled
18 substance not authorized by his registration, or to
19 distribute or dispense a controlled substance not
20 authorized by his registration to another registrant or
21 other authorized person; or

22 (3) to refuse or fail to make, keep or furnish any
23 record, notification, order form, statement, invoice or
24 information required under this Act; or

25 (4) to refuse an entry into any premises for any

1 inspection authorized by this Act; or

2 (5) knowingly to keep or maintain any store, shop,
3 warehouse, dwelling, building, vehicle, boat, aircraft, or
4 other structure or place, which is resorted to by a person
5 unlawfully possessing controlled substances, or which is
6 used for possessing, manufacturing, dispensing or
7 distributing controlled substances in violation of this
8 Act.

9 Any person who violates this subsection (a) is guilty of a
10 Class A misdemeanor for the first offense and a Class 4 felony
11 for each subsequent offense. The fine for each subsequent
12 offense shall not be more than \$100,000. In addition, any
13 practitioner who is found guilty of violating this subsection
14 (a) is subject to suspension and revocation of his professional
15 license, in accordance with such procedures as are provided by
16 law for the taking of disciplinary action with regard to the
17 license of said practitioner's profession.

18 (b) It is unlawful for any person knowingly:

19 (1) to distribute, as a registrant, a controlled
20 substance classified in Schedule I or II, except pursuant
21 to an order form as required by Section 307 of this Act; or

22 (2) to use, in the course of the manufacture or
23 distribution of a controlled substance, a registration
24 number which is fictitious, revoked, suspended, or issued
25 to another person; or

26 (3) to acquire or obtain possession of a controlled

1 substance by misrepresentation, fraud, forgery, deception
2 or subterfuge; or

3 (4) to furnish false or fraudulent material
4 information in, or omit any material information from, any
5 application, report or other document required to be kept
6 or filed under this Act, or any record required to be kept
7 by this Act; or

8 (5) to make, distribute or possess any punch, die,
9 plate, stone or other thing designed to print, imprint or
10 reproduce the trademark, trade name or other identifying
11 mark, imprint or device of another, or any likeness of any
12 of the foregoing, upon any controlled substance or
13 container or labeling thereof so as to render the drug a
14 counterfeit substance; or

15 (6) to possess without authorization, blank
16 prescription forms or counterfeit prescription forms; or

17 (7) (Blank).

18 Any person who violates this subsection (b) is guilty of a
19 Class 4 felony for the first offense and a Class 3 felony for
20 each subsequent offense. The fine for the first offense shall
21 be not more than \$100,000. The fine for each subsequent offense
22 shall not be more than \$200,000.

23 (c) (Blank) ~~A person who knowingly or intentionally~~
24 ~~violates Section 316, 317, 318, or 319 is guilty of a Class A~~
25 ~~misdemeanor.~~

26 (Source: P.A. 91-576, eff. 4-1-00.)

1 (720 ILCS 570/316 rep.)

2 (720 ILCS 570/317 rep.)

3 (720 ILCS 570/318 rep.)

4 (720 ILCS 570/319 rep.)

5 (720 ILCS 570/320 rep.)

6 Section 10. The Illinois Controlled Substances Act is
7 amended by repealing Sections 316, 317, 318, 319, and 320.

8 Section 99. Effective date. This Act takes effect January
9 1, 2008.

1 INDEX

2 Statutes amended in order of appearance

3 720 ILCS 570/313 from Ch. 56 1/2, par. 1313

4 720 ILCS 570/316.5 new

5 720 ILCS 570/406 from Ch. 56 1/2, par. 1406

6 720 ILCS 570/316 rep.

7 720 ILCS 570/317 rep.

8 720 ILCS 570/318 rep.

9 720 ILCS 570/319 rep.

10 720 ILCS 570/320 rep.